The state of cost-effectiveness analysis in American managed care

Richard T. Meenan, David H. Smith, Mark C. Hornbrook, Jeffrey Fellows, Frances L. Lynch, Mark Helfand

Research output: Contribution to journalArticle

Abstract

In 1996, the US Panel on Cost-Effectiveness in Health and Medicine published detailed recommendations for the conduct and use of cost-effectiveness analyses (CEA) of medical technologies. These recommendations were expected to promote the use of CEA to inform the resource allocation decisions of a diverse audience including, among others, American managed care organizations. Yet, nearly 10 years later, the limited explicit use of CEA in the USA remains a prominent discussion topic, with few signs of resolution. Its limited use within managed care is especially striking given the industry's stated interest in efficient healthcare and historically unstable finances in the face of continually rising healthcare costs.

Original languageEnglish (US)
Pages (from-to)229-237
Number of pages9
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume6
Issue number2
DOIs
StatePublished - Apr 2006

Fingerprint

Managed Care Programs
Cost-Benefit Analysis
Resource Allocation
Health Care Costs
Industry
Medicine
Organizations
Technology
Delivery of Health Care
Health

Keywords

  • Budget impact analysis
  • Business case
  • Cost analysis
  • Cost-benefit analysis
  • Cost-effectiveness analysis
  • Economic evaluation
  • Managed care
  • Return on investment

ASJC Scopus subject areas

  • Pharmacology
  • Medicine (miscellaneous)

Cite this

The state of cost-effectiveness analysis in American managed care. / Meenan, Richard T.; Smith, David H.; Hornbrook, Mark C.; Fellows, Jeffrey; Lynch, Frances L.; Helfand, Mark.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 6, No. 2, 04.2006, p. 229-237.

Research output: Contribution to journalArticle

Meenan, Richard T. ; Smith, David H. ; Hornbrook, Mark C. ; Fellows, Jeffrey ; Lynch, Frances L. ; Helfand, Mark. / The state of cost-effectiveness analysis in American managed care. In: Expert Review of Pharmacoeconomics and Outcomes Research. 2006 ; Vol. 6, No. 2. pp. 229-237.
@article{8557984258c74d339dba932d403666e3,
title = "The state of cost-effectiveness analysis in American managed care",
abstract = "In 1996, the US Panel on Cost-Effectiveness in Health and Medicine published detailed recommendations for the conduct and use of cost-effectiveness analyses (CEA) of medical technologies. These recommendations were expected to promote the use of CEA to inform the resource allocation decisions of a diverse audience including, among others, American managed care organizations. Yet, nearly 10 years later, the limited explicit use of CEA in the USA remains a prominent discussion topic, with few signs of resolution. Its limited use within managed care is especially striking given the industry's stated interest in efficient healthcare and historically unstable finances in the face of continually rising healthcare costs.",
keywords = "Budget impact analysis, Business case, Cost analysis, Cost-benefit analysis, Cost-effectiveness analysis, Economic evaluation, Managed care, Return on investment",
author = "Meenan, {Richard T.} and Smith, {David H.} and Hornbrook, {Mark C.} and Jeffrey Fellows and Lynch, {Frances L.} and Mark Helfand",
year = "2006",
month = "4",
doi = "10.1586/14737167.6.2.229",
language = "English (US)",
volume = "6",
pages = "229--237",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - The state of cost-effectiveness analysis in American managed care

AU - Meenan, Richard T.

AU - Smith, David H.

AU - Hornbrook, Mark C.

AU - Fellows, Jeffrey

AU - Lynch, Frances L.

AU - Helfand, Mark

PY - 2006/4

Y1 - 2006/4

N2 - In 1996, the US Panel on Cost-Effectiveness in Health and Medicine published detailed recommendations for the conduct and use of cost-effectiveness analyses (CEA) of medical technologies. These recommendations were expected to promote the use of CEA to inform the resource allocation decisions of a diverse audience including, among others, American managed care organizations. Yet, nearly 10 years later, the limited explicit use of CEA in the USA remains a prominent discussion topic, with few signs of resolution. Its limited use within managed care is especially striking given the industry's stated interest in efficient healthcare and historically unstable finances in the face of continually rising healthcare costs.

AB - In 1996, the US Panel on Cost-Effectiveness in Health and Medicine published detailed recommendations for the conduct and use of cost-effectiveness analyses (CEA) of medical technologies. These recommendations were expected to promote the use of CEA to inform the resource allocation decisions of a diverse audience including, among others, American managed care organizations. Yet, nearly 10 years later, the limited explicit use of CEA in the USA remains a prominent discussion topic, with few signs of resolution. Its limited use within managed care is especially striking given the industry's stated interest in efficient healthcare and historically unstable finances in the face of continually rising healthcare costs.

KW - Budget impact analysis

KW - Business case

KW - Cost analysis

KW - Cost-benefit analysis

KW - Cost-effectiveness analysis

KW - Economic evaluation

KW - Managed care

KW - Return on investment

UR - http://www.scopus.com/inward/record.url?scp=33646089661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646089661&partnerID=8YFLogxK

U2 - 10.1586/14737167.6.2.229

DO - 10.1586/14737167.6.2.229

M3 - Article

C2 - 20528558

AN - SCOPUS:33646089661

VL - 6

SP - 229

EP - 237

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 2

ER -